In this cohort study including 4871 patients, GLP-1 RA use was associated with significant reductions in MACCE, all-cause mortality, new-onset heart failure, decompensated heart failure, and acute kidney injury or end-stage kidney disease over a median follow-up of 3.2 years. The gene discussed is GLP1R; the disease is acute kidney injury.